X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3189) 3189
Book Review (241) 241
Publication (198) 198
Magazine Article (7) 7
Conference Proceeding (4) 4
Book Chapter (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2880) 2880
valine - analogs & derivatives (1879) 1879
humans (1871) 1871
male (1798) 1798
animals (1321) 1321
female (1237) 1237
valine - administration & dosage (957) 957
valsartan (916) 916
valine - therapeutic use (809) 809
rats (771) 771
middle aged (768) 768
valine - pharmacology (754) 754
adult (701) 701
acyclovir - analogs & derivatives (527) 527
aged (527) 527
pharmacology & pharmacy (469) 469
valine (453) 453
tetrazoles - administration & dosage (439) 439
tetrazoles - therapeutic use (409) 409
hypertension - drug therapy (404) 404
treatment outcome (360) 360
drug therapy, combination (315) 315
tetrazoles - pharmacology (314) 314
acyclovir - therapeutic use (312) 312
valine - metabolism (309) 309
blood pressure - drug effects (308) 308
antiviral agents - therapeutic use (307) 307
hypertension (305) 305
abridged index medicus (299) 299
dose-response relationship, drug (298) 298
neurosciences (293) 293
time factors (283) 283
mice (281) 281
valine - adverse effects (280) 280
acyclovir - administration & dosage (278) 278
antihypertensive agents - administration & dosage (267) 267
administration, oral (264) 264
double-blind method (253) 253
amino acids (252) 252
antiviral agents - administration & dosage (250) 250
antihypertensive agents - therapeutic use (246) 246
leucine (221) 221
research (219) 219
valacyclovir (212) 212
peripheral vascular disease (211) 211
valine - pharmacokinetics (204) 204
rats, sprague-dawley (203) 203
valine - blood (196) 196
metabolism (194) 194
isoleucine (182) 182
analysis (179) 179
adolescent (178) 178
drug therapy (174) 174
acyclovir (173) 173
angiotensin ii type 1 receptor blockers - therapeutic use (169) 169
valine - genetics (166) 166
hypertension - physiopathology (160) 160
tetrazoles - adverse effects (160) 160
risk factors (145) 145
biochemistry & molecular biology (144) 144
health aspects (143) 143
angiotensin ii type 1 receptor blockers - administration & dosage (141) 141
proteins (139) 139
angiotensin receptor antagonists (138) 138
physiological aspects (138) 138
rats, wistar (138) 138
diet (135) 135
blood-pressure (134) 134
antihypertensive agents - pharmacology (133) 133
angiotensin ii type 1 receptor blockers - pharmacology (131) 131
blood pressure (131) 131
disease (130) 130
double-blind (130) 130
prospective studies (129) 129
valine - chemistry (129) 129
medicine, general & internal (128) 128
care and treatment (127) 127
cardiac & cardiovascular systems (126) 126
prevention (126) 126
therapy (126) 126
angiotensin (122) 122
aged, 80 and over (118) 118
drug administration schedule (116) 116
dosage and administration (115) 115
physiology (115) 115
rats, inbred strains (114) 114
in vitro techniques (113) 113
article (112) 112
young adult (112) 112
antihypertensive agents - adverse effects (110) 110
mortality (110) 110
disease models, animal (107) 107
medicine, research & experimental (107) 107
amino acids - blood (106) 106
excitatory amino acid antagonists - pharmacology (106) 106
leucine - metabolism (104) 104
medicine (104) 104
methionine - genetics (104) 104
oncology (104) 104
amino acids - metabolism (103) 103
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3060) 3060
German (39) 39
Russian (25) 25
French (20) 20
Japanese (20) 20
Chinese (11) 11
Spanish (8) 8
Swedish (5) 5
Italian (3) 3
Hungarian (2) 2
Norwegian (2) 2
Romanian (2) 2
Danish (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Heart Failure, ISSN 1388-9842, 08/2005, Volume 7, Issue 5, pp. 710 - 721
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of... 
Heart failure | Isosorbide dinitrate | Beta‐blockers | Digoxin | Angiotensin receptor blockers | Pharmacology | Aldosterone antagonists | Treatment | Eplerenone | Spironolactone | Hydralazine | ACE inhibitors | Clinical recommendations | Beta-blockers | VENTRICULAR SYSTOLIC DYSFUNCTION | heart failure | treatment | CARDIAC & CARDIOVASCULAR SYSTEMS | angiotensin receptor blockers | QUALITY-OF-CARE | hydralazine | eplerenone | isosorbide dinitrate | RANDOMIZED INTERVENTION TRIAL | beta-blockers | MEDICAL-TREATMENT | GENERAL-PRACTICE | digoxin | spironolactone | CONVERTING-ENZYME-INHIBITORS | clinical recommendations | CARDIAC-INSUFFICIENCY | pharmacology | NATIONAL-SURVEY | aldosterone antagonists | ELDERLY-PATIENTS | Benzopyrans - therapeutic use | Valsartan | Angiotensin Receptor Antagonists | Bisoprolol - therapeutic use | Humans | Carbazoles - administration & dosage | Heart Failure - physiopathology | Valine - administration & dosage | Enalapril - therapeutic use | Ethanolamines - administration & dosage | Indoles - administration & dosage | Ramipril - administration & dosage | Captopril - therapeutic use | Propanolamines - therapeutic use | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Ramipril - therapeutic use | Drug Therapy, Combination | Enalapril - administration & dosage | Spironolactone - therapeutic use | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Benzimidazoles - therapeutic use | Lisinopril - administration & dosage | Nebivolol | Valine - analogs & derivatives | Metoprolol - therapeutic use | Metoprolol - administration & dosage | Evidence-Based Medicine | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Bisoprolol - administration & dosage | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Benzopyrans - administration & dosage | Captopril - administration & dosage | Guideline Adherence | Ethanolamines - therapeutic use | Indoles - therapeutic use | Metoprolol - analogs & derivatives | Tetrazoles - therapeutic use | Valine - therapeutic use | Carbazoles - therapeutic use | Propanolamines - administration & dosage | Practice Guidelines as Topic | Prescription writing | Corticosteroids | Isosorbide mononitrate | Family medicine | Nitrates | Peptide hormones | Aldosterone | Preventive health services | Cardiac patients | Angiotensin | Antiandrogens | Medicine, Preventive | Steroids | Index Medicus | Kardiologi | converting-enzyme-inhibitors | Cardiac and Cardiovascular Systems | randomized intervention trial | quality-of-care | elderly-patients | cardiac-insufficiency | national-survey | medical-treatment | ventricular systolic dysfunction | general-practice
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 8/2006, Volume 23, Issue 8, pp. 1842 - 1849
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9932, pp. 1889 - 1898
Summary Background The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | MONOTHERAPY | METAANALYSIS | BETA-BLOCKERS | TOLERABILITY | Benzopyrans - adverse effects | Ethanolamines - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzopyrans - therapeutic use | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Valine - administration & dosage | Ethanolamines - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Tetrazoles - administration & dosage | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Nebivolol | Double-Blind Method | Drug Administration Schedule | Valine - analogs & derivatives | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Benzopyrans - administration & dosage | Ethanolamines - therapeutic use | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Drug Combinations | Hypertension | Usage | Patient outcomes | Dosage and administration | Drug therapy | Oxidative stress | Health Insurance Portability & Accountability Act 1996-US | Cardiovascular disease | Blood pressure | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2006, Volume 47, Issue 4, pp. 726 - 733
OBJECTIVES: We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic... 
MORTALITY | CHRONIC HEART-FAILURE | HIGH-RISK PATIENTS | CARDIAC & CARDIOVASCULAR SYSTEMS | LEFT-VENTRICULAR DYSFUNCTION | CARDIOVASCULAR EVENTS | II TYPE-1 RECEPTOR | RANDOMIZED-TRIAL | CONVERTING-ENZYME INHIBITOR | HYPERTENSIVE PATIENTS | BASE-LINE CHARACTERISTICS | Recurrence | Valsartan | Angina Pectoris - prevention & control | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Valine - administration & dosage | Captopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Tetrazoles - administration & dosage | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Stroke - prevention & control | Valine - analogs & derivatives | Atherosclerosis - complications | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Myocardial Infarction - complications | Captopril - administration & dosage | Myocardial Infarction - drug therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Myocardial Infarction - prevention & control | Heart attacks | Drug therapy | Mortality | Coronary vessels | Index Medicus | Abridged Index Medicus | Valine/administration & dosage/analogs & derivatives/therapeutic use | Angina Pectoris/prevention & control | dosage/therapeutic use | Cardiovascular Diseases/mortality/prevention & control | Myocardial Infarction/complications/drug therapy/prevention & control | Drug Therapy | Angiotensin-Converting Enzyme Inhibitors/administration | Atherosclerosis/complications | Captopril/administration & dosage/therapeutic use | Kardiologi | Cardiac and Cardiovascular Systems | Randomized Controlled Trials | Combination | Tetrazoles/administration & dosage/therapeutic use | Cerebrovascular Accident/prevention & control | Angiotensin II Type 1 Receptor Blockers/administration
Journal Article
by Jacquemard and Yamamoto and Costa and Romand and Jaqz-Aigrain and Dejean and Daffos and Ville
BJOG: An International Journal of Obstetrics & Gynaecology, ISSN 1470-0328, 09/2007, Volume 114, Issue 9, pp. 1113 - 1121
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2008, Volume 48, Issue 1, pp. 85 - 95
We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction... 
Type 2 diabetes | Angiotensin converting enzyme inhibitor | Calcium channel blocker | Dipeptidyl peptidase IV inhibitor | Vildagliptin | Angiotensin receptor blocker | Pharmacokinetics | LAF237 | RISK | angiotensin receptor blocker | PHARMACODYNAMICS | BLOOD-PRESSURE | DIABETES-MELLITUS | BIOTRANSFORMATION | type 2 diabetes | vildagliptin | calcium channel blocker | angiotensin converting enzyme inhibitor | MEN | pharmacokinetics | PHARMACOLOGY & PHARMACY | HYPERTENSION | TYPE-2 | STAGE RENAL-DISEASE | dipeptidyl peptidase IV inhibitor | Nausea - chemically induced | Tablets | Humans | Middle Aged | Half-Life | Pyrrolidines - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Nitriles - pharmacokinetics | Ramipril - administration & dosage | Drug Interactions | Tetrazoles - administration & dosage | Ramipril - analogs & derivatives | Adamantane - administration & dosage | Ramipril - adverse effects | Amlodipine - administration & dosage | Adamantane - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Administration, Oral | Pyrrolidines - pharmacokinetics | Amlodipine - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Valine - adverse effects | Nitriles - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Valsartan | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Pyrrolidines - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics | Valine - administration & dosage | Nitriles - administration & dosage | Amlodipine - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Headache - chemically induced | Adamantane - pharmacokinetics | Adamantane - adverse effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Ramipril - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Tetrazoles - adverse effects | Amlodipine | Dosage and administration | Enzyme inhibitors | Research | Index Medicus
Journal Article
Hypertension, ISSN 0194-911X, 06/2010, Volume 55, Issue 6, pp. 1314 - 1322
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2012, Volume 56, Issue 5, pp. 2251 - 2258
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
IN-VITRO | ENTRY | HIV | PROTECTION | MICROBICIDES | PREVENTION | RESISTANCE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | SEXUAL TRANSMISSION | WATER | HIV Infections - prevention & control | Triazoles - administration & dosage | Vagina - drug effects | Humans | Administration, Intravaginal | Cyclohexanes - administration & dosage | Macaca mulatta | Chromatography, High Pressure Liquid | Valine - administration & dosage | Virus Internalization - drug effects | Delayed-Action Preparations - administration & dosage | Anti-HIV Agents - administration & dosage | Tissue Distribution | Simian Acquired Immunodeficiency Syndrome - virology | HIV-1 - physiology | Female | Triazoles - pharmacokinetics | Pyrazoles - pharmacokinetics | CCR5 Receptor Antagonists | HIV-1 - drug effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Contraceptive Devices, Female | Simian Acquired Immunodeficiency Syndrome - blood | Simian Immunodeficiency Virus - physiology | Simian Acquired Immunodeficiency Syndrome - prevention & control | Pyrazoles - administration & dosage | Animals | Biopsy | Anti-HIV Agents - pharmacokinetics | Vagina - virology | Medroxyprogesterone Acetate - administration & dosage | Cyclohexanes - pharmacokinetics | Longitudinal Studies | Simian Immunodeficiency Virus - drug effects | Index Medicus | Antiviral agents | Experimental Therapeutics
Journal Article
Journal Article
10.